- Oral presentation will feature HS235, the Company’s Phase 1 Activin and GDF inhibitor for cardiometabolic disease and obesity
- HS235 improved body composition, and rescued left ventricular function and exercise capacity in a murine obese HFpEF model
Montreal, QC, Canada (Nov 03, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at ObesityWeek® 2024 in San Antonio, TX, USA (Nov 3-6, 2024).
HS235 is an Fc-fused ligand trap that selectively and potently neutralizes pathological Activins and growth differentiation factors (GDFs). The Company has recently been cleared to commence Phase 1 clinical testing of HS235 in overweight and obese healthy subjects, and anticipates sharing initial data from this trial during the second half of 2025.
During an oral presentation at Obesity Week 2024, 35Pharma Chief Scientific Officer Maureen O’Connor will share pre-clinical data with HS235 demonstrating its dual metabolic and cardiac activity in a murine model of obese Heart Failure with preserved Ejection Fraction (HFpEF).
In this heart failure model, HS235 treatment positively impacted both cardiac function and metabolic health. Specifically, HS235 administration resulted in:
- decrease in fat mass, including pericardial fat
- increase in muscle mass
- rescue of left ventricular function
- reduction of circulating NT-proBNP, a biomarker of heart failure
- return of exercise capacity to the levels of lean control
Details of the upcoming presentation at ObesityWeek® are as follows:
Title: HS235, a Novel Activin and GDF Ligand Trap, Is Efficacious in a Model of Obesity-Related HFpEF (Oral-030)
Session: Corporate Orals Session 1
Date & Time: November 4th, 2024, 8:30 AM – 8:45 AM
Location: Henry B. González Convention Center, San Antonio, TX, Room 207
About 35Pharma
35Pharma is a clinical-stage biopharmaceutical company focused on the design and development of best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for Pulmonary Hypertension, obesity and cardiometabolic diseases. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta superfamily ligands while sparing beneficial homeostatic ligands.
Contact
Julia Schoelermann, VP Corporate Development, 35Pharma
info@35pharma.com
For more information, please visit www.35pharma.com
